Latest Health News

Oliver's Real Food reported a 25.8% increase in net loss to $2.91 million for FY2025 despite a 23.5% rise in core earnings before impairments, driven by operational restructuring and store closures.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Rhythm Biosciences has significantly reduced its annual loss by 44%, boosted by a 91% rise in other income, while launching a new wholly owned subsidiary, RHY GeneType Pty Ltd.

Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.

AJ Lucas Group Limited has reported a sharp decline in its financial results for FY2025, with revenue down 8.5% and a net loss soaring to $15 million. The company also recorded a significant drop in EBITDA and profit before interest and tax, signaling tough times ahead.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.

xReality Group (XRG) reports a landmark FY25 with 36% revenue growth driven by its Operator XR platform and a major US law enforcement contract. The company’s strategic shift towards immersive training technology signals robust momentum into FY26.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

RBR Group Limited reported an 88% plunge in revenue and a widening net loss for FY2025, impacted by political instability and LNG project delays in Mozambique. The company is investing in facility upgrades and workforce training to position itself for a market rebound.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.